The reduced cash burn extends runway into Q3 2026, providing time for potential catalysts including CMA submission in Europe and Phase 1b data from CLR 125. However, the company will likely need to raise capital before year-end 2026. Investors should monitor upcoming regulatory and clinical milestones as potential value drivers.
Price Chart
Executive Summary
Cellectar Biosciences reported its 2025 financial results, showing a significantly reduced net loss of $21.8M compared to $44.6M in 2024, driven by lower R&D and G&A expenses. The company highlighted clinical and regulatory progress, including plans to submit a Conditional Marketing Authorization in Europe for iopofosine I-131 in Waldenström Macroglobulinemia in 2026 and the initiation of a Phase 1b trial for CLR 125 in triple-negative breast cancer.
Key Financial Metrics
Key Facts
- Cash and cash equivalents decreased from $23.3M (2024) to $13.2M (2025), expected to fund operations into Q3 2026.
- R&D expenses dropped from $26.1M in 2024 to $11.5M in 2025 due to reduced clinical activity in the CLOVER WaM study.
- G&A expenses declined from $25.6M to $11.5M year-over-year, reflecting reduced pre-commercialization efforts.
- Net loss narrowed to $21.8M ($8.35/share) from $44.6M ($36.52/share) in 2024.
- Company plans CMA submission for iopofosine I-131 in Waldenström Macroglobulinemia to EMA in Q3 2026.
- Phase 1b dose-finding study for CLR 125 in TNBC initiated, with early data expected by mid-2026.
Financial Impact
Net loss reduced by $22.8M YoY; cash burn decreased significantly, but cash balance now stands at $13.2M with runway into Q3 2026.
Risk Factors
- Limited cash runway beyond Q3 2026 necessitates future financing, which may be dilutive given the current $11M market cap.
- Reliance on regulatory approval pathways with no guarantee of CMA acceptance or FDA approval.
- Clinical development risks in ongoing and future trials, particularly in new indications like TNBC.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3249235 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | Press Release | $1.19 | awaiting T+60 | — | $1.22 (+2.52%) |
Aug 13, 2026 10w ago | 8-K | $2.48 | awaiting T+60 | — | $1.22 (−50.81%) |
Aug 13, 2026 10w ago | Press Release | $2.48 | awaiting T+60 | — | $1.22 (−50.81%) |
Jun 1, 2026 21w ago | Press Release | $2.97 $2.54 | ▼ −14.48% | ▼ −15.71% | $1.22 (−58.92%) |
May 29, 2026 21w ago | S-1/A | $3.14 $2.52 | ▲ +19.75% | ▲ +20.93% | $1.22 (+61.15%) |
May 28, 2026 21w ago | DEFA14A | $3.14 $2.52 | ▼ −19.75% | ▼ −20.93% | $1.22 (−61.15%) |
May 19, 2026 22w ago | S-1 | $3.17 $2.60 | ▲ +17.98% | ▲ +22.98% | $1.22 (+61.51%) |
May 14, 2026 23w ago | 8-K | $3.20 $2.60 | ▼ −18.75% | ▼ −22.34% | $1.22 (−61.87%) |
May 14, 2026 23w ago | Press Release | $3.20 $2.60 | ▼ −18.75% | ▼ −22.34% | $1.22 (−61.87%) |
May 11, 2026 24w ago | Press Release | $3.06 $2.52 | ▼ −17.65% | ▼ −22.04% | $1.22 (−60.13%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers